Our Mission
Non-invasively targeting biofilm at the implants' surface
Born from research at UT Southwestern Medical Center, Solenic Medical is advancing a new standard in implant infection care. Our technology is designed to target biofilm at the implant surface, where persistent bacterial communities can make standard antibiotics up to 1,000 times less effective and turn routine treatment into a costly, high-risk clinical challenge.
Using patented alternating magnetic field technology, Solenic is developing a noninvasive approach to disrupt and potentially eradicate biofilm without repeat surgery. The goal is broader, more effective treatment for infections associated with implanted medical devices, starting with some of the most difficult cases in orthopedic care.
What drives us
Principles that shape every decision we make
Patient at the Center
Non-invasive by design
Clinical precision
Adaptive over time
Evidence-first culture
Radical transparency
Non-invasive by design
AMF fields penetrate tissue without loss of strength, while the thermal effect (skin effect) remains confined to less than 1 mm from the implant surface—precisely where infection resides—resulting in minimal to no impact on surrounding tissue and eliminating the need for implant removal.
Clinical precision
AMF precisely targets the metal–biofilm interface at the implant surface, where biofilm can make standard antibiotics up to 1,000 times less effective by limiting their penetration, rather than affecting the bloodstream or surrounding tissue.
Adaptive over time
Biofilm is not static; it progresses through distinct stages—attachment, microcolony formation, maturation, and dispersal—and responds to treatment pressure, while clinical signals such as elevated ESR and mixed-pathogen infections may predict recurrence.
Evidence-first culture
Our AMF platform is grounded in peer-reviewed in vivo data from a preclinical murine model (Shaikh et al., 2023), demonstrating a greater than 1-log reduction in bacterial biofilm burden, synergy with antibiotics, and activity against both gram-positive and gram-negative pathogens.
Patient at the Center
Periprosthetic joint infection carries a 10-year mortality rate of up to 45%, comparable to many malignancies; more than half of affected patients report depression or regret, and fewer than one in three working-age patients return to employment after revision surgery.
Radical transparency
The literature is clear that progress in implant infection care depends on open, multidisciplinary collaboration among surgeons, microbiologists, engineers, and clinicians, as well as continued research to translate innovations into clinical practice. We publish our findings transparently—including the preclinical status of AMF and the need for further clinical validation—because the field advances faster when evidence is shared.
Our People
A team built across disciplines
Solving prosthetic joint infection demands more than engineering it requires microbiologists, orthopedic surgeons, infectious disease specialists, biomedical engineers, and clinical scientists working from a shared evidence base. Solenic was built on that premise. Our team spans disciplines because the problem demands it and our progress reflects it.
Leadership
Board of Directors
Medical Advisory Board
